Nebenwirkungen · Opdivo
OPDIVO 10 mg/mL concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 29–30
HOS-133363 · Präparat HOS-097426
29 chemotherapy (n = 1800), and nivolumab in combination with cabozantinib (n = 320) are presented in Table 19. These reactions are presented by system organ class and by frequency. Frequencies are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to < 1/1 000), not known (cannot be estimated from available post-marketing data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-19T11:11:00Z · SHA-256 1ce21ede7b3b9a8abc396626f301d2db3510ede7261a38fc34a275e7a180f454 · Passage 512f3b3a2a1878a60116cb90376427cf015830327de921e6e529d83a8df6a9c5 · Zeichen 14775–15272 im Abschnitt